GSK (GSK) News Today → Crypto Pioneer Says: “The last crypto bull market has begun.” (From InvestorPlace) (Ad) Free GSK Stock Alerts GBX 1,775.72 +0.73 (+0.04%) (As of 04:55 AM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsDividendHeadlinesInsider TradesSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsDividendHeadlinesInsider TradesSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 16, 2024 | lse.co.ukTOP NEWS: GSK to sell remaining holding in spin-off HaleonMay 16, 2024 | msn.comGSK to sell entire Haleon stakeMay 15, 2024 | msn.comGSK chief calls for more investment to combat drug-resistant bacteriaMay 14, 2024 | finanznachrichten.deThe Department of Health - Abu Dhabi: Department of Health - Abu Dhabi partners with GSK to Establish Regional Vaccine Distribution HubMay 14, 2024 | finance.yahoo.comDepartment of Health - Abu Dhabi partners with GSK to Establish Regional Vaccine Distribution HubMay 14, 2024 | americanbankingnews.comGSK (LON:GSK) Sets New 1-Year High at $1,821.00May 10, 2024 | americanbankingnews.comGSK (LON:GSK) Reaches New 1-Year High at $1,767.50May 9, 2024 | forbes.comBuy Write Grabs Next Week’s Dividend From GSKMay 9, 2024 | finance.yahoo.comGSK (LON:GSK) Is Paying Out A Dividend Of £0.15May 8, 2024 | marketbeat.comGSK (LON:GSK) Reaches New 12-Month High at $1,767.50GSK (LON:GSK) Sets New 12-Month High at $1,767.50May 7, 2024 | marketbeat.comGSK's (GSK) Equal Weight Rating Reiterated at BarclaysBarclays reiterated an "equal weight" rating and issued a GBX 1,725 ($21.67) price objective on shares of GSK in a research report on Tuesday.May 6, 2024 | finance.yahoo.comGSK Stock Today: Buying An August Covered Call Boosts Your Return By This MuchMay 5, 2024 | finance.yahoo.comGSK plc (NYSE:GSK) Q1 2024 Earnings Call TranscriptMay 2, 2024 | bloomberg.comGSK, Boehringer Put Profits Over User Safety, Zantac Jury ToldMay 2, 2024 | msn.comModerna to seek parity for RSV shot as rivals lead in marketMay 2, 2024 | marketbeat.comGSK (LON:GSK) Price Target Increased to GBX 1,660 by Analysts at JPMorgan Chase & Co.JPMorgan Chase & Co. boosted their price objective on shares of GSK from GBX 1,530 ($19.22) to GBX 1,660 ($20.85) and gave the stock an "underweight" rating in a research note on Thursday.May 2, 2024 | marketbeat.comGSK (LON:GSK) Sets New 1-Year High After Dividend AnnouncementGSK (LON:GSK) Sets New 12-Month High After Dividend AnnouncementMay 1, 2024 | marketbeat.comGSK plc (LON:GSK) to Issue GBX 15 DividendGSK plc (LON:GSK) declared a dividend on Wednesday, May 1st. Investors of record on Thursday, May 16th will be paid a dividend of GBX 15 ($0.19) per share on Thursday, July 11th. This represents a yield of 0.9%. The ex-dividend date of this dividend is Thursday, May 16th. The official announcement can be seen at this link.May 1, 2024 | marketbeat.comGSK (LON:GSK) Earns Buy Rating from Shore CapitalShore Capital reiterated a "buy" rating on shares of GSK in a report on Wednesday.May 1, 2024 | morningstar.comGSK Lifts Guidance After Turnover Beats Expectations — UpdateMay 1, 2024 | msn.comGSK Non-GAAP EPS of 43.10p, revenue of £7.4B; updates FY24 outlookApril 30, 2024 | finance.yahoo.comGenomics plc and GSK establish precision medicine collaboration to assess polygenic risk scores in clinical trial designApril 30, 2024 | marketwatch.comGSK Turnover, Net Profit Expected to Rise as Investors Seek Zantac Litigation Clarity -- Earnings PreviewApril 24, 2024 | msn.comSCI, GSK launches $1m initiative to boost immunisation rate in Nigeria, EthiopiaApril 24, 2024 | msn.comUS regulator accepts GSK’s application to expand treatment of cancer drugApril 24, 2024 | ft.comGSK readies for pivotal ruling in Zantac casesApril 19, 2024 | seekingalpha.comGSK Trades At Low Price Multiples, But Its Pipeline Needs To ImproveApril 18, 2024 | finance.yahoo.comGSK Canada expands charitable partnerships to include support of environmental sustainability and STEMApril 17, 2024 | marketbeat.comDeutsche Bank Aktiengesellschaft Reaffirms "Buy" Rating for GSK (LON:GSK)Deutsche Bank Aktiengesellschaft reiterated a "buy" rating and issued a GBX 1,950 ($24.27) target price on shares of GSK in a research note on Wednesday.April 16, 2024 | finance.yahoo.comGSK May 2024 28.000 call (GSK240517C00028000)April 16, 2024 | seekingalpha.comLyell Immunopharma: Testing The T-Cell Thesis With 2 Upcoming Data CatalystsApril 16, 2024 | finance.yahoo.comBrainStorm Cell Therapeutics Announces Management Changes as Company Plans Registrational Phase 3b Trial of NurOwnApril 16, 2024 | lse.co.ukGSK's latest meningitis vaccine accepted for review by US regulatorApril 16, 2024 | markets.businessinsider.comFDA Accepts GSK's 5-in-1 Meningococcal ABCWY Vaccine Candidate For Regulatory ReviewApril 14, 2024 | marketbeat.comGSK plc (LON:GSK) Given Average Rating of "Hold" by AnalystsShares of GSK plc (LON:GSK - Get Free Report) have earned a consensus rating of "Hold" from the seven brokerages that are presently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and three have givenApril 12, 2024 | finance.yahoo.comGSK plc: GSK's Strong Vaccine and HIV Portfolios Support Steady GrowthApril 11, 2024 | msn.comWall Street's Most Accurate Analysts' Views On 3 Health Care Stocks With Over 3% Dividend YieldsApril 11, 2024 | msn.comDemocrats push more drug makers to lower the price of inhalersApril 11, 2024 | forbes.comWill Biopharma Companies Shun Vaccine R&D In A New Pandemic?April 8, 2024 | marketbeat.comGSK (LON:GSK) Earns "Equal Weight" Rating from BarclaysBarclays reissued an "equal weight" rating and issued a GBX 1,725 ($21.65) target price on shares of GSK in a research note on Monday.April 3, 2024 | marketbeat.comAkebia Therapeutics Surges on FDA Approval for Anemia Treatment (GSK)Akebia Therapeutics Inc. (NASDAQ: AKBA) is a biopharmaceutical company specializing in developing treatments for chronic kidney diseases (CKD) and anemiaApril 2, 2024 | markets.businessinsider.comBuy Rating Affirmed for SCYNEXIS on Ibrexafungerp Success and Strong GSK PartnershipApril 2, 2024 | seekingalpha.comScynexis: Update Following Restructuring Of GSK DealApril 2, 2024 | seekingalpha.comAkebia's Vafseo Faces Grim Market Outlook (Rating Downgrade)March 28, 2024 | bizjournals.comFormer GSK office building in Navy Yard set for sheriff's sale to satisfy $78M foreclosure judgmentMarch 23, 2024 | insidertrades.comInsider Buying: GSK plc (LON:GSK) Insider Buys 434 Shares of StockMarch 22, 2024 | marketbeat.comGSK plc (LON:GSK) Insider Buys £7,213.08 in StockGSK plc (LON:GSK - Get Free Report) insider Urs Rohner bought 434 shares of the business's stock in a transaction that occurred on Wednesday, March 20th. The shares were acquired at an average price of GBX 1,662 ($21.16) per share, with a total value of £7,213.08 ($9,182.79).March 21, 2024 | benzinga.comSenator Bernie Sanders Applauds GSK's Move To Cap Inhaler Costs At $35 Per MonthMarch 20, 2024 | markets.businessinsider.comSosei Regains Full Ownership From GSK Of Clinic-Ready GPR35 Agonist For Inflammatory Bowel DiseaseMarch 20, 2024 | reuters.comGSK to cap out-of-pocket inhaler costs in US Get GSK News Delivered to You Automatically Sign up to receive the latest news and ratings for GSK and its competitors with MarketBeat's FREE daily newsletter. Email Address Urgent Nvidia Warning (Ad)Could Steve Job's 'Final Prophecy' Make You Rich? Just before he died, Steve Jobs issued a "Final Prophecy" that's now coming true... and making some people rich. In one recent 90-day stretch, 50 companies related to Jobs' "Final Prophecy" soared by 100% or more. What was Steve Jobs' last big prediction, and how can you get in on it? Professor Joel Litman explains everything... including the surprising group of stocks moving higher, and his No. 1 favorite stock in this space. Click here to access… GSK Media Mentions By Week GSK Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GSK News Sentiment▼0.120.42▲Average Medical News Sentiment GSK News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GSK Articles This Week▼67▲GSK Articles Average Week Get GSK News Delivered to You Automatically Sign up to receive the latest news and ratings for GSK and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: AZN News Today HLN News Today DPH News Today SN News Today CTEC News Today HIK News Today HCM News Today INDV News Today GNS News Today EMIS News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (LON:GSK) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersShocking: One AI startup's revenue could surge 4,735%Manward PressThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaNext President (Not Trump. Not Biden.)The Freeport SocietyUrgent Nvidia WarningAltimetryElon’s New Device is About to Shock the WorldInvestorPlace"The Biggest Drug Ever" Is ComingBehind the MarketsCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GSK plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
